Latest News in Sickle Cell Disease
Announcement from ASH about Sickle Cell Disease
The American Society of Hematology just released their priorities for sickle cell research. First of all, the President of ASH acknowledged that, despite research and advancements, the current way sickle cell is treated and managed falls short of successful care.
Developed with a wide group of researchers and healthcare providers, seven research areas were identified as priorities in Sickle Cell Research.
Organ damage: to better understand the risk and progression to the essential organs of the body (eg, heart, kidneys, etc.)
Pain: to better understand what processes are behind the pain, to develop new treatments for pain
Therapies: how to best use the therapies available, such as hydroxyurea and blood transfusions, to discover the best medications and doses for individuals living with SCD
New drugs to treat SCD that can prevent organ damage
Greater investment in a cure, including different new approaches, such as partial transplants and other therapies
Guidelines: how useful they are and whether they’re being utilized in the real world
Sickle cell trait: including genetic counseling and family planning.
Source: firstwordpharma.com/ Am Soc Hematology
Research is ongoing on sickle cell disease, and you don’t have to search for it alone. Know Rare has a support team that can help guide you. Contact us here.
Pfizer pulls Sickle Cell Disease Drug Off the Market
Following a number of deaths in clinical studies for Oxbryta (voxelotor), which was approved as a treatment for sickle cell disease in 35 countries, Pfizer decided to proactively withdraw the drug from being marketed. Pfizer took over the drug when it acquired Global Blood Therapeutics, and the drug works by preventing the clumping together of hemoglobin into the sickle shape and by breaking it down.
Pfizer’s Chief Medical Officer was responsible for the decision, after a review of the results of two clinical trials testing the drug, one in children who were at higher risk of stroke, and the other in a study of the effect of the drug on leg ulcers, which happens to people with SCD. In the first study of 236 people over age 12, there were 8 deaths in the group taking the drug (vs 2 in those taking placebo), and in the second study, of 88 participants all taking the drug (but may also be taking something else) there were 8 who died.
Although the European Medical Association (EMA) said there was not enough evidence to assume the deaths were caused by the medication alone, Pfizer is voluntarily pulling it off the market, since the medical officer believes the medication’s benefit is not enough to justify the risk of death.
A drug is not approved by the FDA unless it has undergone multiple stages of testing, across many people. What’s interesting about Pfizer’s decision is that the serious effect occurred in a specific population in both cases, and it is not clear whether the same risks would apply to the general SCD population. However, it seems Pfizer believes that, when safety concerns arise, it may be better to take no chances.
This is a setback for people with SCD since another treatment option has failed.
If you or your loved one is diagnosed with sickle cell disease and would like to learn about the latest research opportunities, you can contact the Know Rare support team below:
Latest from Know Rare
From prenatal uncertainty and postpartum anxiety to therapy, grief, and hope, a mother shares her experience raising a child with a rare disease, navigating the healthcare system, finding community, and learning to embrace a different—but deeply meaningful—path as a parent.
A Danon disease study, led by researcher Dr. Barry Greenberg and published in the New England Journal of Medicine, wins an award! The study focuses on gene therapy as a potential treatment option for Danon disease. The study showed early signs that gene therapy may help the hearts of people with Danon disease.
A poster, presented at the European Hematology Association meeting in June, described a study that looked at tiredness (fatigue) in adults with immune thrombocytopenia (ITP). Researchers wanted to see if fatigue was related to bleeding or other health test results.
Lucky Shanmugan was recently featured in Porter Ranch Living, his local magazine, for Father’s Day: in his interview, Lucky talks about Osteogenesis Imperfecta, a rare genetic or heritable disorder of the connective tissue, and the incredible journey towards his official diagnosis.
Here are 9 things Chris Anselmo wishes someone had told him after his rare disease diagnosis.
A family’s hardships and resilience in finding answers and getting a diagnosis for their child, after numerous tests, brain biopsies, and hospitalizations. And the relief but also grief in finally putting a name to the rare disease that affects their child: BCL11B-related disorder.
The Danon Foundation boldly empowers people living with Danon disease, providing trusted information, resources and support to help navigate life, from diagnosis to treatment.
For many families, caregiving for a child with a rare or medically complex condition is a full-time job. The problem is, it’s a job with no training, no time off, and no clear job description. If you’re looking for the light at the end of the tunnel, you don’t have to search alone. Check out some of Paige’s favorite resources.
For most of celiacs, despite months on a strict GF diet, energy stays low and blood work reveals nutrient deficiencies. The lesson? A "gluten-free" label isn't a health guarantee—just a guarantee you'll pay more.
If you’ve been told you have seronegative NMOSD, there’s nearly 50/50 chance you have a different antibody causing your symptoms –MOG antibody.
Therapy Near Me is a nationwide mental health service based in Australia, providing easy access to psychologists, counsellors, behaviour support practitioners and social workers.
At the annual Kidney Week of the American Society of Nephrologists (ASN), the world’s largest kidney healthcare professional organization, new advances in research were highlighted. Over $35 million has been invested in research with the ASN, and there are many treatments in development for IgA Nephropathy (IgAN), with researchers actively investigating more than 20 different drugs.
When I was diagnosed with celiac disease, I thought avoiding bread and pasta would be enough. I quickly learned that living truly gluten-free is far more complex, and I'm sharing my experience to help newly diagnosed individuals understand what lies ahead.
Retinopathy is an eye problem that many people with Danon disease have. It can cause dark spots in the outer part of the eye, blurry or worse vision, and unusual test results on an eye exam. Sometimes these eye changes show up before heart problems, so an eye check can help find the disease early.
A heartfelt story about a mother who found purpose and strength among the tragedy of losing a child diagnosed with an ultra rare genetic disorder.
Kaya Girl Legacy, Inc. is a Florida-based nonprofit founded in memory of Kaya Humbert, a beautiful baby girl born with Sphingosine Phosphate Lyase Insufficiency Syndrome (SPLIS), one of 46 known cases worldwide. The foundation is dedicated to empowering families with knowledge about their genetic health and advocating for early access to genetic testing and rare disease awareness.
A prose poem by Jim Kuhn, a rare warrior living with Sarcoidosis, a rare inflammatory disease.
Rare Mom Laura shares how her family’s prep for Halloween turned into a burst of familial love and creativity, as they all worked together in designing and building a costume for Alden, her medically complex son.
Instead of starting with a newly discovered drug compound, PCOR is a type of research that starts by turning to patients and caregivers and asking, What matters most to you? What questions do we want answered? What symptoms do we wish were better managed? What keeps us up at night?
Four years ago, Michael Grivas’ life suddenly changed when he learned that he had Brugada Syndrome, a genetic disorder in which the electrical activity of the heart is abnormal due to channelopathy. Learn more about his story.
Fatigue is a very common and often debilitating symptom of IgAN. It is linked to disease progression and reduced kidney function, but other factors like inflammation, anemia, and mental health also play a role. In a 2025 study, the majority of patients with IgAN reported fatigue, and patients with more severe proteinuria and lower kidney filtration rates (eGFR) experienced worse fatigue.
Why is it so hard to accept help? Humans often associate help with weakness and loss of independence and control. However, if we reframe our thoughts, accepting help can be viewed as a form of empowerment: showing vulnerability and trusting someone to help us requires great strength.
There is so much mental load with having a rare disease. Rare Human Lindsay shares there are things she does not care about anymore, as she manages rare disease symptoms, specialists, and clinical trials.
Rare Human Lindsay shares her "silver linings." It's not 'what doesn't kill you makes you stronger,' instead it's what doesn't kill you makes you braver. She shares that she has found deeper connections with others, improved her ability to ask for and accept help, and not been as afraid of the word "no."
Journalist and rare disease advocate Lindsay Guentzel breaks down why clinical trials are a lifeline for the rare disease community. With only 5% of known rare diseases having an FDA-approved therapy, trials often represent the only path toward treatment, progress, and hope.
Lindsay was diagnosed with dermatomyositis a couple of years ago. Since then, she has undergone more than 350 doctor appointments, 250+ hours of infusions, 10+ ER visits, while juggling insurance approvals, rides, and her pain and fatigue.
Rare Human Lindsay is in the midst of her first clinical trial for dermatomyositis, a rare inflammatory disease that primarily affects the skin and muscles. So far, she has learned so much about the process and is eager to share some of her insights with the rare disease community.